The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
YakesFMChenJTanJ. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
KurzrockRShermanSHongD. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) [abstract 379]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theurapeutics; Geneva; 2008.
KurzrockRShermanSIBallDW. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666.
SchoffskiPEliseiRMüllerS. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline [abstract 5508]. Proc Am Soc Clin Oncol. 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94113. Accessed February 1, 2013.
NemunaitisJMitaAStephensonJ. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol. 2013;71(1):35–41.
CortesJLiptonJHReaD. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573–2580.
NicoliniFELiptonJHKantarjianH. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs) [abstract 6513]. Proc Am Soc Clin Oncol. 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100567. Accessed February 1, 2013.
29.
LiptonJHWetzlerMNicoliniFE. Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): analysis of two phase II studies [abstract 6568]. Proc Am Soc Clin Oncol. 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54142. Accessed February 1, 2013.
30.
Quintás-CardamaAKantarjianHGarcia-ManeroG. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109(2):248–255.
31.
CoonleyCJWarrellRPYoungCW. Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep. 1983;67(7-8):693–696.
32.
ZhaoTPDingGXGaoHY. A clinical trial of homoharringtonine in the treatment of advanced breast cancer. Tumori. 1986;72(4):395–398.
33.
LiYFDengZKXuanHB. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Chin Med J (Engl). 2009;122(12):1413–1417.
34.
O'BrienSKantarjianHKollerC. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999;93:4149-4153.
35.
O'BrienSKantarjianHKeatingM. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86(9):3322–3326.
36.
HuangBTZengQCYuJ. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China. Med Oncol. 2012;29(1):251–259.
37.
LeghaSSKeatingMPicketS. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984;68(9):1085–1091.
38.
LévyVZoharSBardinC. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer. 2006;95(3):253–259.
39.
FeldmanEJSeiterKPAhmedT. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996;10(1):40–42.
40.
FeldmanEArlinZAhmedT. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia. 1992;6(11):1185–1188.
41.
BellBAChangMNWeinsteinHJ. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol. 2001;37(2):103–107.
